Access type

Forgot your password? Click here

DMP_ForgotOK Close


If you are a doctor or a journalist not yet registered at the Dompé reserved areas, click here to fill in the form.



Dompé leads the project for the creation of the International Research Centre

Abruzzo Regione della Vista (Region of Sight): Dompé leads the project for the creation of the International Research Centre

Milan, 29th August 2015. It all began at Expo Milano 2015. The programme agreement for the creation of the "Abruzzo Regione della Vista" (Region of Sight) Ophthalmology Research and Innovation Centre was signed in the futuristic Italian Pavilion, within the framework of "Capitank Forum", the event dedicated to "Life sciences in Abruzzo: Opportunities for New Development". Dompé's partners in the project include the Regional Centre of Excellence in Ophthalmology of the "Gabriele D'Annunzio" University of Chieti-Pescara, the Abruzzo Region, and Capitank, a regional chemical and pharmaceutical innovation centre.

The objective of the agreement is to initiate a coordinated action for the conduct of pre-clinical and clinical research and trials in technological areas related to eye disorders (dry eye, glaucoma, corneal diseases, retinitis pigmentosa and optic neuropathies).

The "Abruzzo Regione della Vista" (Region of Sight) Research and Innovation Centre has been created as part of the 2015-17 Regional Economic and Financial Planning Document (Documento Programmazione Economico-Finanziaria Regionale - DPEFR) to strengthen the region's research and technology transfer system by enhancing relationships between universities, regional research centres and businesses. The goal is to make L'Aquila and the entire regional territory able to attract potential investors in ophthalmological research excellence.

This innovative project will be led by Dompé, an Italian biopharmaceutical company focused on Research & Development of innovative therapeutic solutions for rare and orphan diseases, including ophthalmologic disorders.

“When we talk about Research & Development, striving for innovation is imperative. Today, finding innovative responses to ophthalmic diseases is as challenging as it is necessary. Against this backdrop, our Research initiative has chosen as its hub the Abruzzo Region, a territory that has been able to create a model: that model has become a system, with a scientific community based on public-private partnerships ,", said Eugenio Aringhieri, Dompé CEOone of the speakers at the round table organised to present the agreement at the conclusion of the "Capitank Forum".“This is why we have strongly supported the programme agreement for the creation of the "Abruzzo Regione della Vista" (Region of Sight) Ophthalmology Research and Innovation Centre as the natural outcome of this virtuous system, with a twofold objective: on the one hand, to promote the conduct of research studies and trials for the development of new therapeutic solutions; on the other, to reinforce a model which, being based on the strength of the network, can be competitive in an international arena less and less conditioned by local constraints and increasingly inclined to recognise the ability to generate added value."

In ophthalmology, the Group is committed to developing potential therapeutic responses for rare eye diseases and for the treatment of the most prevalent conditions such as dry eye syndrome. In particular, Dompé has initiated international trials aimed at demonstrating the efficacy and safety of recombinant human Nerve Growth Factor, the molecule discovered by Nobel Prize winner Rita Levi Montalcini. A study named REPARO is underway in 9 European countries for the treatment of neurotrophic keratitis, a rare disease for which no cure exists; another study, called LUMOS, is being conducted for the treatment of retinitis pigmentosa, a disorder that affects the back of the eye. Dry eye syndrome, which affects the ocular surface, is another condition for which Dompé is considering the use of rhNGF, with a phase II study.

Abruzzo Regione della Vista" (Region of Sight) will help to develop innovative technologies and to disseminate part of the resulting methods and discoveries throughout the industry's entire manufacturing sector, recognized to be among the most flourishing in the country. This process has been made possible by the project's stated goals of promoting the technological development of Abruzzo-based application sectors linked to the reference areas of the recently signed programme agreement.

This synergy is important not only for the future treatment of ophthalmological diseases, but also for the Region's productive fabric and research.